Skip to content

Reproductive Harms: Ovarian Inflammation and Miscarriages

Day 3 · 0:41:47 · Deanna McLeod · Dean Allison

  • 🧬 Biodistribution shows lipid nanoparticles accumulate in ovaries, driving a 34% jump in oophoritis and menstrual disorders.
  • 👶 Ontario miscarriage rates rose from 225 to 275 per 100,000 after mRNA rollout; corrected trial data indicated far higher loss rates.
  • 🚫 A halted pregnancy RCT showed doubled congenital malformations in the vaccine arm—data that remained buried.

Fertility and pregnancy signals emerge from both biodistribution and population data.

← Post-Rollout Surges in Hospitalizations and Chronic Conditions | Adam Burgess Sworn: Remembering Sister Christy →

Transcript

Deanna McLeod · 0:41:47

Okay, so I'm going to just shift into reproductive health because again, we had a couple people talk about loss of, um, babies. So on the left-hand side is the biodistribution data and I've highlighted the black box or the red box there is that the LNPs are little fat molecules and ovaries are hungry for those. And so the LNPs accumulate in the ovaries. They're also inflammatory, so causing inflammation. So inflammation of the ovaries is basically, will impact your fertility. So if you look on the right, the OHIP code 614 for oophoritis, which is swelling of the ovaries, is right there. And you can see that at the peak after COVID, which it was going down previously prior to COVID, and then after that you have this dramatic jump in 2021, a 34% increase versus what would be expected in oophoritis, which means swelling of the ovaries.

Deanna McLeod · 0:42:47

So this is basically having a dramatic impact on many women's ovaries. So disorders of menstruation, it's not surprising that you'll see menstrual disorders. So again, we have issues of—.

Dean Allison · 0:42:58

Diana, you have a minute left, and I'm sorry about that.

Deanna McLeod · 0:43:03

I'm going to keep going. So female fertility, male fertility issues, pregnancy loss. It was in the New England Journal of Medicine. Oh, sorry, I'm going back. Let's just go here. The New England Journal of Medicine, there was an error where they said it was 12.6% miscarriage rates. We tried to correct that because The actual data said that it was 82% in and around that if you actually looked at the right denominator. And here it is, that's what it looks like on a population level. Um, you roll out an mRNA product and you get miscarriages. So that line there is 225 per 100,000 and it jumped up to 275 per 100,000.

Dean Allison · 0:43:41

This is Province of Ontario.

Deanna McLeod · 0:43:43

This is Ontario. Yeah, that's what it looks like whenever you don't do your safety testing. So there was something that talked about fetal malformation. If you actually— they did do a randomized control trial in pregnant women that they stopped whenever they basically approved the vaccine. But if you actually go and look at congenital malformation, it's double in the vaccine arm versus placebo. So this data was buried.

Dean Allison · 0:44:06

And I have to stop you, but you're going to be here today and tomorrow. We may recall you. Yep. To give you more time if, if we have find ourselves with a break because I think everyone is finding this very important. And the fact that this is new research using Province of Ontario data is quite striking.

Deanna McLeod · 0:44:25

All right, well, I'm here. Let me know.

Dean Allison · 0:44:29

And I'm sorry about that, but—.

Deanna McLeod · 0:44:30

No, no, I know.

Dean Allison · 0:44:31

We did know when we shoehorned you in that we'd have to be tight with time. And I think I can speak for— or Dean.

Dean Allison · 0:44:37

Yeah, no, thank you. Yeah, thank you very much for being here and providing annual You'll be providing the, the decks and we'll be providing them online as well. And hopefully we can, we can take you back up to finish it off. Okay, thanks.